Apart from targeting the mutated EGFR, our findings unravel an alternative potential strategy to counteract the acquired-gefitinib-resistance phenotype through the modulation of ER stress response elements, and shed light on the potential benefit of combining FO and Se for relieving the acquired resistance of NSCLC patients to targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.